EU Guides On ATMP Trials, Genetically Modified Cells To Be Finalized This Year
Executive Summary
The 2020 work plan of the European Medicines Agency’s committee on advanced therapies shows that two keenly-awaited guidelines are due to be finalized this year.
You may also be interested in...
EMA Consults On Data Requirements For Cell And Gene Therapy Trials
The European Medicines Agency's draft guideline on investigational advanced therapy medicinal products makes a clear distinction between exploratory and confirmatory clinical trials as the classical approach of distinguishing between various stages of a clinical trial is not as well defined for such products.
EMA Reviewing Guide To Support New Genome Editing Technologies, CAR-T Cell Therapies
The European Medicines Agency is updating its five-year old guideline on drugs containing genetically modified cells to factor in rapid scientific developments in relation to gene editing technologies, and the development of promising new cancer immunotherapies, such as CAR-T cells.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.